Marjolein S de Bruin-Weller

51PUBLICATIONS
154CO-AUTHORS
Gene and molecular therapyPharmacogenomicsGlycoconjugatesAdolescent healthEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Aug 07, 2026
Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

|Jun 01, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

|Jan 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Eric L Simpson, Robert Bissonnette, Mette Deleuran

|Sep 24, 2025
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions.

Marjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten

|Sep 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).

Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas

|Jul 31, 2025
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry.

Florence Vroman, Lisa P van der Rijst, Octavian I Bacoş-Cosma

Pageof 9

Frequent Collaborators

12 joint publications

Judith Thijs

12 joint publications

Daphne S Bakker

7 joint publications

Marlies de Graaf

6 joint publications

Coco Dekkers